Saturday 17 October 2026 Export PSNL’s income statement to Excel — free account

Personalis, Inc.

Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS fell 30.4% and free cash flow fell 123.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

15.65 0.28 −1.76%

Follow PSNL

Alert me

Market cap: $1.7B
P/E: 0.0×
Fwd P/E: −10.5×
Dividend yield: —
F-score: 4/9
Altman Z: 3.35
Beneish M: −1.30
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.74

Total sells 8.78

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	1	—	—	—	2	4	2	—	4	—

Insider Ownership 31.75%

Capital & Financial Ratios $m

Market Cap 1,700.00

Revenue 69.67

Net Income (107.18)

Free Cash Flow (100.85)

Net Debt (212.66)

Current Ratio 5.28

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (10.50)

P/S ratio 23.68

P/B ratio 7.02

Past 5Y EPS Growth —

This Y EPS Growth (19.51%)

Next Y EPS Growth 13.79%

Next Y revenue growth 21.09%

Next 5Y EPS Growth 10.38%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 97.71%

10-year low 10-year high

P/B against its own 10 years 94.50%

10-year low 10-year high

EV/Sales against its own 10 years 96.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	114	185	240	213
Receivables	18	8	16	15
Inventory	10	6	6	10
Other	—	—	—	—
	147	203	268	245

	2023	2024	2025	Q'26
Payables	15	6	13	16
ST’ Debt	—	—	—	—
Other	8	3	2	3
	47	31	40	46

Compound Annual Growth %

	10y	5y	3y
Sales	—	(2.40%)	2.30%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	6.02%	6.19%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	22	—	—	—
’25	21	17	14	17	70
’24	20	23	26	17	85
’23	19	17	18	20	73
’22	15	18	15	17	65
’21	21	22	22	21	85
’20	19	19	20	20	79

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(26)	—	—	—
’25	(18)	(13)	(22)	(22)	(75)
’24	(20)	(11)	(6)	(8)	(45)
’23	(16)	(10)	(17)	(13)	(56)
’22	(11)	(27)	(15)	(17)	(70)
’21	(12)	(26)	(18)	(15)	(71)
’20	(9)	(15)	(16)	(3)	(43)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(30)	—	—	—
’25	(20)	(13)	(23)	(22)	(79)
’24	(21)	(11)	(6)	(9)	(47)
’23	(20)	(13)	(18)	(17)	(67)
’22	(20)	(38)	(36)	(26)	(120)
’21	(12)	(30)	(21)	(19)	(82)
’20	(9)	(16)	(18)	(3)	(46)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.29)	(0.30)	—	—	—
’25	(0.18)	(0.23)	(0.24)	(0.26)	(0.91)
’24	(0.26)	(0.24)	(0.64)	(0.23)	(1.37)
’23	(0.61)	(0.50)	(0.60)	(0.54)	(2.25)
’22	(0.63)	(0.60)	(0.58)	(0.67)	(2.48)
’21	(0.29)	(0.34)	(0.40)	(0.45)	(1.49)
’20	(0.29)	(0.29)	(0.27)	(0.34)	(1.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	8.48	4.27	11.62	1.73	0.89	1.12	2.83	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	31.88	46.80	53.46	14.57	4.31	7.20	11.40
People
People	Employees	—	—	147	182	235	326	399	225	229	260
	Revenue/emp, $m	—	0.00	0.26	0.36	0.33	0.26	0.16	0.33	0.37	0.27
Income, $m
Income, $m	Revenue	—	9	38	65	79	85	65	73	85	70
	Gross margin, %	—	(24.94)	31.25	33.86	25.57	37.03	20.52	24.78	31.70	22.65
	EBT	—	(24)	(20)	(25)	(41)	(65)	(113)	(108)	(81)	(81)
	EBT margin, %	—	(251.18)	(52.63)	(38.45)	(52.41)	(76.28)	(174.14)	(147.27)	(96.04)	(116.66)
	Net income	—	(24)	(20)	(25)	(41)	(65)	(113)	(108)	(81)	(81)
	Depreciation	—	1	3	5	6	8	8	9	8	6
Per share, $
Per share, $	Revenue	—	3.10	12.33	3.62	2.29	1.95	1.42	1.53	1.43	0.78
	Earnings	—	(7.78)	(6.49)	(1.39)	(1.20)	(1.49)	(2.48)	(2.25)	(1.37)	(0.91)
	Cash flow	—	0.10	1.82	(1.00)	(1.24)	(1.61)	(1.54)	(1.17)	(0.76)	(0.84)
	Capex	—	(1.70)	(2.56)	(0.47)	(0.09)	(0.25)	(1.09)	(0.23)	(0.02)	(0.05)
	Free cash flow	—	(1.61)	(0.74)	(1.47)	(1.34)	(1.87)	(2.63)	(1.39)	(0.78)	(0.89)
	Book value	—	0.00	(34.73)	5.92	5.67	7.07	4.77	2.69	3.43	2.93
	Shares, m	—	3	3	18	34	44	46	48	59	89
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	3.01	16.00	7.33	1.41	1.34	4.05	10.20
	P/B	—	0.00	0.00	1.84	6.46	2.02	0.42	0.76	1.69	2.72
	EV/Sales	—	0.00	0.00	1.32	13.65	4.18	(0.89)	0.03	2.07	7.01
	EV/FCF	—	(21.53)	(21.53)	(3.25)	(23.38)	(4.36)	0.48	(0.03)	(3.77)	(6.15)
Cash, $m
Cash, $m	Operating cash flow	—	0	6	(18)	(43)	(71)	(70)	(56)	(45)	(75)
	Capex	—	(5)	(8)	(8)	(3)	(11)	(50)	(11)	(1)	(5)
	Free cash flow	—	(5)	(2)	(26)	(46)	(82)	(120)	(67)	(47)	(79)
Balance, $m
Balance, $m	Working capital	—	(23)	(28)	90	180	287	167	100	172	228
	Total debt	—	18	6	2	11	60	49	—	—	—
	Net debt	—	(23)	(20)	(128)	(203)	(287)	(168)	(114)	(185)	(240)
	Shareholders’ equity	—	—	(106)	107	195	310	218	129	203	261
Returns, %
Returns, %	ROA	—	(62.73)	(95.45)	(25.21)	(20.53)	(20.34)	(32.88)	(41.83)	(32.82)	(26.89)
	ROIC	—	0.00	0.00	0.00	0.00	(175.78)	(143.04)	(450.20)	(237.72)	(259.21)
	ROE	—	23.72	19.99	(16,611.92)	(27.37)	(25.82)	(42.89)	(62.31)	(48.91)	(35.02)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
Median of peers	$2.8B	29.9×	99.4×	+17.82%	—	+37.50%	71.13%	(3.61%)

All 52 Diagnostics & Research stocks →

Personalis, Inc. (PSNL) key facts

Concern: Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
Concern: Personalis, Inc. reported a net loss of $81.3 million, or a loss of $0.91 per share, for fiscal 2025.
Personalis, Inc. (PSNL) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PSNL traded at $15.65, a market capitalization of $1.7 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 23.7× sales.
Return on equity was −35.0% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.35 (safe zone) for fiscal 2025.